Merck’s Recombivax Vaccine Shortage Causes Reduced Deaths In Babies | WHAT REALLY HAPPENED


Merck’s Recombivax Vaccine Shortage Causes Reduced Deaths In Babies

Following the cyber-attack in June 2017, for the first time in a very long time, researchers have the ability to view in plain sight, a natural experiment whereby one vaccine was abruptly swapped out for another – replacing the very adjuvant many critics are concerned about, AAHS – with an aluminum hydroxide adjuvant contained in Engerix-B. Neither has a published independent safety profile but AAHS is suspected to be more problematic due to its immunogenicity profile.

We now have more than a year’s worth of data to examine since the attack in 2017 when Engerix-B was introduced. On average there were 29 deaths reported annually for fifteen years prior to the attack (2003 to 2017). In 2018 there were only 6 reported (to end of November 2018). Two of those deaths followed Recombivax. Assuming the same death rate to the end of the year, at most there will be 7 deaths recorded, resulting in roughly 75% less deaths since Recombivax was discontinued as a pediatric vaccine.

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA